Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers

Abstract

Background

This study aimed at monitoring the kinetics of serum total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in a cohort of healthcare workers after voluntary vaccination with Pfizer-BioNTech coronavirus disease 2019 (COVID-19) mRNA-based vaccine.

Methods

The study population consisted of 787 healthcare workers (mean age 44±12 years; 66% females), who received two 30 mg doses of Pfizer-BioNTech COVID-19 vaccine, 3 weeks apart. Venous blood was drawn before the first vaccine dose, immediately before the second vaccine dose, and then at 1, 3 and 6 months after the second vaccine dose. Serological testing employed the total antiSARS-CoV-2 antibodies measurement with Roche Elecsys Anti-SARS-CoV-2 S chemiluminescent immunoassay.

Results

The median serum levels of total anti-SARS-CoV-2 antibodies reached the peak (1762 kU/L) 1 month after the second vaccine dose, but tended to progressively decline at the 3-month (1086 kU/L) and 6-month (802 kU/L) follow-up points. Overall, the values after 3and 6months were 37% and 57% lower than the corresponding concentrations measured at the peak. No healthcare worker had total anti-SARS-CoV-2 antibodies below the method-dependent cut-off after 6 months. The decline compared to the peak was more accentuated in baseline seropositive persons than in those who were baseline seronegative (74% vs. 52%) cohort. The 6-month post-vaccination anti-SARS-CoV-2 antibodies in subjects aged <65 years remained over 2-fold higher than in those aged ≥65 years (813 vs. 343 kU/L) and also remained consistently higher in women than in men.

Conclusions

Gradual decline of total anti-SARS-CoV-2 antibodies occurred 6 months after Pfizer-BioNTech COVID-19 vaccination, though values remained higher than the method-dependent cut-off, with no case of sero-negativization.

Introduction

There is now consolidated evidence that the onset of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection in healthcare facilities is associated with an enhanced risk of morbidity and mortality, both in hospitalized patients as well as in healthcare workers. Therefore, regular SARS-CoV-2 diagnostic testing and coronavirus disease 2019 (COVID-19) vaccination are now regarded as major cornerstones for preventing and/or limiting the burden of SARS-CoV-2 inside and outside healthcare facilities [1]. A recent study published by Yoshimura et al. [2] evidenced a fairly good response in terms of anti-SARS-CoV-2 IgG level after a complete cycle of Pfizer BNT162b2 mRNA-based COVID-19 vaccine. Since it is now acknowledged that large part of vaccine effectiveness is attributable to the generation of anti-SARS-CoV-2 antibodies of different classes and with different antigenic targets [3], but capable to quickly and efficiently neutralize viral particles inside the host, regular assessment of these antibodies seems essential for monitoring immune protection among healthcare workers, especially given that serum levels of most vaccine-induced antibodies are observed to decline over time [4]. This study was hence aimed at monitoring the kinetics of serum total anti-SARS-CoV-2 antibodies in a cohort of healthcare workers who underwent voluntary administration of Pfizer-BioNTech COVID-19 mRNA-based vaccine.

Materials and Methods

The study population consisted of 787 healthcare workers of Peschiera del Garda hospital in Italy (mean age 44±12 years; 66% females), who received two 30 mg doses of Pfizer-BioNTech COVID-19 vaccine, 3 weeks apart. Venous blood was drawn before the first vaccine dose, immediately before the second vaccine dose (i.e., 21 days after the first dose), and then at 1, 3 and 6 months after the second vaccine dose (51, 111 and 201 days after the first vaccine dose). Serological testing was based on total anti-SARS-CoV-2 antibodies measurement with Roche Elecsys Anti-SARS-CoV-2 S chemiluminescent immunoassay, on Roche Cobas 6000 (Roche Diagnostics, Basel, Switzerland; positive result: ≥0.8 kU/L). Recent evidence suggests that this method reliably mirrors the overall SARS-CoV-2 neutralizing potential developed after COVID-19 vaccination, with sensitivity as high as 98% compared to a pseudovirus neutralization test [5]. Test results were reported as median and interquartile range (IQR), and the statistical analysis was performed using Analyse-it (Analyse-it Software Ltd, Leeds, UK). Between-group comparisons were carried out with Mann-Whitney test. All study participants gave informed consents for vaccination and undergoing serial anti-SARS-CoV-2 antibodies monitoring. This observational study was reviewed and cleared by the Ethics Committee of Verona and Rovigo provinces (3246CESC).

Results

The main results of this study are shown in Figure 1. The median serum levels of total anti-SARS-CoV-2 antibodies reached the peak (1762 kU/L; IQR, 933–3761 kU/L) 1 month after the second vaccine dose (i.e., 51 days after the first vaccine dose), but then tended to progressively decline at the 3-month (i.e., 111 days after the first vaccine dose: 1086 kU/L; IQR, 629–2155 kU/L) and 6-month (i.e., 201 days after the first vaccine dose: 802 kU/L; IQR, 447–1487 kU/L) follow-up points. Overall, the serum values after 3-and 6-months were 37% (IQR, 15–53%; p<0.001) and 57% (IQR, 35–71%; p<0.001) lower than the corresponding concentrations measured at the peak, respectively. Notably, no healthcare worker had total anti-SARS-CoV-2 antibodies below the method-dependent cut-off (i.e., 0.8 kU/L) at either the 3- or 6-month follow-up points. Notably, the relative decline of serum antibodies values compared to the peak was more accentuated in baseline seropositive (74%; IQR, 62–82%) persons than in those who were baseline seronegative (52%; IQR, 31–67%) cohort. A decrease of serum total anti-SARS-CoV-2 antibodies levels occurred in 576/624 (92.3%) baseline seronegative subjects and in 160/163 (98.1%) seropositive subjects. The 6-month post-vaccination serum level of total anti-SARS-CoV-2 antibodies in subjects aged <65 years (n=754; 813 KUL; IQR, 473-1501 kU/L) remained over 2-fold higher than that measured in those aged ≥65 years (n=33; 343 kU/L; IQR, 210-903 kU/L; p<0.001), and also remained consistently higher in women than in men (Figure 2). The relative decrease of the serum level of total anti-SARS-CoV-2 antibodies compared to the peak after 3 and 6 months from vaccination is also shown in Figure 3, where a very similar trend can be seen despite the rather different peak levels (Figure 3).

Figure 1. Kinetics of total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) serum antibodies in a cohort of healthcare workers who underwent voluntary administration of two doses of Pfizer-BioNTech COVID-19 mRNA-based vaccine.

Figure 2. Kinetics of total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) serum antibodies in a cohort of healthcare workers who underwent voluntary administration of two doses of Pfizer-BioNTech COVID-19 mRNA-based vaccine, stratified by age and sex.

Figure 3. The relative decrease of the serum level of total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies compared to the peak after 3 and 6 months from coronavirus disease 2019 (COVID-19) vaccination, stratified by age and sex.

Discussion

The preliminary results of this ad-interim analysis of anti-SARS-CoV-2 humoral immunity in healthcare workers who received a complete (2-dose) cycle of Pfizer-BioNTech COVID-19 vaccination reveal that a gradual decline of total anti-SARS-CoV-2 antibodies (and hence of neutralizing potential) has occ urred 6 months after vaccination, though the antibodies values have remained still considerably higher than the method-dependent cut-off and no seronegativization seems to have occurred in either baseline seronegative or seropositive subjects. These results compared rather well with other preliminary data made available by Bayart and colleagues [6], who also showed that the decay of anti-SARS-CoV-2 RBD total antibodies after 6 months from Pfizer-BioNTech COVID-19 vaccine administration was around 55% in seronegative healthcare workers, thus nearly identical to the 57% decrease that we found in our cohort over an identical period of monitoring. Although better medium-term response would have been theoretically expected in subjects with double immunization (i.e., SARS-CoV-2 infection followed by full vaccination), we instead found that total anti-SARS-CoV-2 antibodies reduction appeared larger in baseline seropositive than seronegative recipients (i.e., 74% vs. 52%) (Figure 2). This is perhaps attributable to the fact that the former cohort also displayed higher peak values, so that the catabolism may have been relatively more pronounced in these subjects. The difference in antibody levels distribution between age and sexes is not really unexpected, since some concomitant studies showed similar trends, with lower immunogenicity been reported in men and in the elderly [7] [8].

Notably, the significantly lower antibodies values found in elderly healthcare male workers (Figure 2) also raises further doubts as to whether further vaccine boosters may be especially advisable in this cohort between 6 and 12 months after completing a regular Pfizer-BioNTech COVID-19 vaccine cycle, to ensure a reinforced protection [9], since this is the most vulnerable population to severe SARS-CoV-2 infection [10].

Dodatak

Research funding

None declared.

Author contributions

All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Informed consent

Informed consent was obtained from all individuals included in this study.

Ethical approval

This observational study was reviewed and cleared by the Ethics Committee of Verona and Rovigo provinces (3246CESC).

Acknowledgments

The authors acknowledge the staff of the Service of Laboratory Medicine of the Pederzoli Hospital (Peschiera del Garda, Italy) for the skill technical assistance.

Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.